SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 229 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $92,576 | -45.4% | 52,600 | -2.6% | 0.00% | -50.0% |
| Q4 2022 | $169,560 | -30.0% | 54,000 | +9.3% | 0.00% | -33.3% |
| Q3 2022 | $242,060 | -25.3% | 49,400 | +37.2% | 0.00% | 0.0% |
| Q3 2021 | $324,000 | -40.7% | 36,000 | -21.1% | 0.00% | -40.0% |
| Q2 2021 | $546,000 | -8.2% | 45,600 | -4.0% | 0.01% | -16.7% |
| Q1 2021 | $595,000 | -1.2% | 47,500 | +23.1% | 0.01% | 0.0% |
| Q4 2020 | $602,000 | +125.5% | 38,600 | +36.4% | 0.01% | +100.0% |
| Q3 2020 | $267,000 | +9.9% | 28,300 | +4.4% | 0.00% | 0.0% |
| Q2 2020 | $243,000 | +135.9% | 27,100 | +68.3% | 0.00% | +200.0% |
| Q1 2020 | $103,000 | -47.2% | 16,100 | -25.1% | 0.00% | -50.0% |
| Q3 2019 | $195,000 | -13.3% | 21,500 | +2.9% | 0.00% | -33.3% |
| Q2 2019 | $225,000 | +27.8% | 20,900 | +13.6% | 0.00% | +50.0% |
| Q1 2019 | $176,000 | -64.7% | 18,400 | -57.7% | 0.00% | -71.4% |
| Q4 2018 | $499,000 | -26.4% | 43,500 | +8.8% | 0.01% | -12.5% |
| Q3 2018 | $678,000 | – | 40,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 6,000,000 | $66,540,000 | 6.69% |
| FIC CAPITAL INC | 787,529 | $8,734,000 | 3.47% |
| RA Capital Management | 1,220,209 | $13,532,000 | 1.36% |
| PRINCETON CAPITAL MANAGEMENT INC | 114,120 | $1,266,000 | 0.67% |
| Perceptive Advisors | 800,000 | $8,872,000 | 0.53% |
| Cormorant Asset Management, LP | 361,000 | $4,003,000 | 0.53% |
| Highlander Capital Management, LLC | 43,500 | $482,000 | 0.43% |
| APEX CAPITAL, LLC | 439,900 | $4,878,000 | 0.42% |
| WASATCH ADVISORS LP | 3,091,386 | $34,283,000 | 0.37% |
| Baker Brothers Advisors | 3,230,932 | $35,831,000 | 0.31% |